Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma

BackgroundImmune checkpoint inhibitor (ICI) therapy dramatically prolongs melanoma survival. Currently, the identified ICI markers are sometimes ineffective. The objective of this study was to identify novel determinants of ICI efficacy.MethodsWe comprehensively curated pretreatment somatic mutation...

Full description

Bibliographic Details
Main Authors:	Wenjing Zhang, Yujia Kong, Yuting Li, Fuyan Shi, Juncheng Lyu, Chao Sheng, Suzhen Wang, Qinghua Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Immunology
Subjects:	melanoma immunotherapy SMGs mutational signatures molecular subtypes predictive biomarkers
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.798474/full

Similar Items

<i>HSPG2</i> Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer
by: Wenjing Zhang, et al.
Published: (2022-07-01)

Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients
by: Qinghua Wang, et al.
Published: (2022-11-01)

The Identification of the Metabolism Subtypes of Skin Cutaneous Melanoma Associated With the Tumor Microenvironment and the Immunotherapy
by: Ronghua Yang, et al.
Published: (2021-08-01)

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
by: Michael F. Gowen, et al.
Published: (2018-04-01)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
by: Michele Guida, et al.
Published: (2021-01-01)

The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma
by: Hao Chen, et al.
Published: (2019-08-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)

Efficacy of immune checkpoint inhibitors in different types of melanoma
by: Ernesto Rossi, et al.
Published: (2021-01-01)

Identification and Validation of <i>RELN</i> Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer
by: Zhenpeng Li, et al.
Published: (2022-11-01)

Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma
by: Zaoqu Liu, et al.
Published: (2021-07-01)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
by: Joel Ho, et al.
Published: (2022-10-01)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
by: Wei Chong, et al.
Published: (2021-03-01)

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
by: Hao Chen, et al.
Published: (2019-05-01)

Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
by: Hao Chen, et al.
Published: (2019-07-01)

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
by: Wenjing Zhang, et al.
Published: (2022-06-01)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
by: Ho-Seok Sa, et al.
Published: (2022-08-01)

Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective
by: Stefano Poletto, et al.
Published: (2023-12-01)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
by: Katarzyna Tomela, et al.
Published: (2020-09-01)

Editorial: Using multi-omics to develop new strategies to improve prognosis and immunotherapy outcomes in cancers
by: Chenxi Cao, et al.
Published: (2023-06-01)

High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade
by: Juan Luis Onieva, et al.
Published: (2022-08-01)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
by: Elizabeth I. Buchbinder, et al.
Published: (2021-04-01)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
by: Jean-Matthieu L’Orphelin, et al.
Published: (2023-04-01)

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
by: Kimberly Loo, et al.
Published: (2022-01-01)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01)

Sequential Treatment With Targeted and Immune Checkpoint Therapy in Patients With BRAF Positive Metastatic Melanoma: The Importance of Timing?
by: Victoria Grätz, et al.
Published: (2019-12-01)

Two subtypes of cutaneous melanoma with distinct mutational signatures and clinico-genomic characteristics
by: Yoon-Seob Kim, et al.
Published: (2022-09-01)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
by: Justin Tong, et al.
Published: (2022-10-01)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
by: Teresa Kim, et al.
Published: (2014-12-01)

Crosstalk of four kinds of cell deaths defines subtypes of cutaneous melanoma for precise immunotherapy and chemotherapy
by: Qi Wan, et al.
Published: (2022-11-01)

Editorial: Molecular Genetics of Cutaneous Melanoma: Current Status and Future Direction
by: Cristina Pellegrini, et al.
Published: (2021-12-01)

Multidisciplinary approach and treatment of acral and mucosal melanoma
by: Ana Fortuna, et al.
Published: (2024-02-01)

Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)
by: David Russo, et al.
Published: (2023-10-01)

Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures
by: Sultana Mehbuba Hossain, et al.
Published: (2022-09-01)

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
by: Marta Morante, et al.
Published: (2022-10-01)

Multiplex immunohistochemistry defines two cholesterol metabolism patterns predicting immunotherapeutic outcomes in gastric cancer
by: Wei Tang, et al.
Published: (2023-12-01)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)

Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma
by: Qian Liu, et al.
Published: (2021-01-01)

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
by: Wengang Zhang, et al.
Published: (2022-11-01)

Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population
by: Oleksandr Dudin, et al.
Published: (2023-03-01)

Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma
by: Huan Luo, et al.
Published: (2020-10-01)